P-169 Does Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Impact Clinical Management? A Canadian Experience.

Background: Infliximab (IFX) is a chimeric (mouse/human) anti-tumor necrosis factor alpha (anti-TNFa) therapy used for treatment of inflammatory bowel disease (IBD). The main phenotypes of IBD are Crohn's disease (CD) and Ulcerative colitis (UC). On biological therapy, patients may become unresponsive to therapy or develop side effects. The reasons for which may be sub-therapeutic drug levels or development of Human Anti-Chimeric Antibodies …